ArticleFrontiers in oncology2018
Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function.
Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Tongguanteng Injection Induces Apoptosis of Colorectal Cancer Cells Via Inhibiting PTGS2 Mediated PD-L1 Checkpoint Pathway: Insights from Network Pharmacology and Experimental Validation.Applied biochemistry and biotechnology · 2026Article
- Tumor Microenvironment, Inflammation, and Inflammatory Prognostic Indices in Diffuse Large B-Cell Lymphomas: A Narrative Review.International journal of molecular sciences · 2025Review
- Aspirin Combined with Antifungal Drugs SuppressesJournal of microbiology and biotechnology · 2025Article
- Concomitant medication effects on patients with lung cancer taking immune checkpoint inhibitors a review.Medical oncology (Northwood, London, England) · 2025Review
- NK cell dysfunction in antiphospholipid syndrome.Frontiers in immunology · 2025Review
- Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Advances.International journal of nanomedicine · 2025Review
- LMP1 mediates tumorigenesis through persistent epigenetic modifications and PGC1β upregulation.Oncology reports · 2023Article
- Aspirin inhibits the biological behavior of gallbladder carcinoma cells by modulating vascular endothelial growth factor.American journal of translational research · 2023Article
- Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.Molecules (Basel, Switzerland) · 2022Review
- Aspirin and cancer: biological mechanisms and clinical outcomes.Open biology · 2022Review
- Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway.Stem cell reviews and reports · 2021Article
- Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway.Frontiers in cell and developmental biology · 2021Article
- Use of Oral Anticoagulation and Diabetes Do Not Inhibit the Angiogenic Potential of Hypoxia Preconditioned Blood-Derived Secretomes.Biomedicines · 2020Article
- Aspirin Induces Mitochondrial CaInternational journal of molecular sciences · 2020Article
- Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer.Journal of cancer research and clinical oncology · 2019Review
- PGC1β Regulates Breast Tumor Growth and Metastasis by SREBP1-Mediated HKDC1 Expression.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal nasal-type natural killer/T-cell lymphoma (NKTCL) is an Epstein-Barr virus (EBV)-associated lymphoma with a strong tendency relapse or be refractory in response to chemotherapy. Development of a new strategy for NKTCL treatment is still quite necessary. In this study, we found that aspirin treatment suppresses VEGF expression in NKTCL SNK-6 cells. Further investigation showed that aspirin treatment increases histone methylation in the range of -100~0 that is proximal to the transcription start site on the VEGF promoter, subsequently decreasing the binding ability of Sp1 to the VEGF promoter with VEGF suppression. Furthermore, aspirin treatment modulates mitochondrial function with increased ROS formation and apoptosis in NKTCL cells. Aspirin treatment alone slightly inhibits NKTCL SNK-6 tumor growth and EBV replication; while in the presence of histone deacetylase inhibitor (HDACi) chidamide (CDM), aspirin significantly suppresses the VEGF signaling pathway with increased ROS overgeneration and EBV inhibition. We also showed that with the addition of chidamide, aspirin significantly suppresses NKTCL tumor growth in both
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.